First Patient Enrolled in Phase I MagSense® HER2+ Breast Cancer Study

This week Imagion Biosystems has announced we have enrolled our first patient into our first clinical study.

This is an important step for our Phase I MagSense® HER2 breast cancer study. The study investigates the use of a MagSense® imaging agent as a means of aiding in the staging of HER2 positive breast cancer by detecting if the patient’s tumor has spread to the lymph nodes.

Read the full announcement here.